Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®
Information source: Bayer
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Telmisartan (Kinzal/Pritor, BAY68-9291) (Drug); Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Bayer Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer
Overall contact:
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Summary
The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed
over 3-4 months
Clinical Details
Official title: Data Collection on Hypertension and Its Treatment With Kinzal®/ Kinzalplus®
Study design: Cohort, Prospective
Primary outcome: Blood pressure
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Hypertensive patients seen by the physician requiring antihypertensive treatment
Exclusion Criteria:
- According to the local drug information
Locations and Contacts
Bayer Clinical Trials Contact, Email: clinical-trials-contact@bayerhealthcare.com
Many Locations, Switzerland; Recruiting
Additional Information
Click here and search for drug information provided by the FDA Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product Click here to find results for studies related to marketed products
Starting date: April 2008
Ending date: April 2010
Last updated: October 12, 2009
|
